Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report

Perry M. Elliott,Aris Anastasakis,Angeliki Asimaki,Cristina Basso,Barbara Bauce,Matthew A. Brooke,Hugh Calkins,Domenico Corrado,Firat Duru,Kathleen J. Green,Daniel P. Judge,David Kelsell,Pier D. Lambiase,William J. McKenna,Kalliopi Pilichou,Alexandros Protonotarios,Jeffrey E. Saffitz,Petros Syrris,Hari Tandri,Anneline Te Riele,Gaetano Thiene,Adalena Tsatsopoulou,J. Peter van Tintelen
DOI: https://doi.org/10.1002/ejhf.1534
2019-06-18
European Journal of Heart Failure
Abstract:<p>It is 35 years since the first description of arrhythmogenic right ventricular cardiomyopathy (ARVC) and more than 20 years since the first reports establishing desmosomal gene mutations as a major cause of the disease. Early advances in the understanding of the clinical, pathological and genetic architecture of ARVC resulted in consensus diagnostic criteria, which proved to be sensitive but not entirely specific for the disease. In more recent years, clinical and genetic data from families and the recognition of a much broader spectrum of structural disorders affecting both ventricles and associated with a propensity to ventricular arrhythmia have raised many questions about pathogenesis, disease terminology and clinical management. In this paper, we present the conclusions of an expert round table that aimed to summarise the current state of the art in arrhythmogenic cardiomyopathies and to define future research priorities.</p>
cardiac & cardiovascular systems
What problem does this paper attempt to address?